Market Incident
Public · Developing
AI compiled from Infoway · 3 analyzed stories
Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven
Carlyle and PAI Partners agreed to sell Theramex, a London-based specialty pharmaceutical company focused on women's health, to rival private equity firm Cinven. The companies did not disclose financial terms, though the Financial Times reported the deal was worth 2.6 billion euros, or $2.9 billion.
Published:
Updated:
What happened
Carlyle and PAI Partners agreed to sell Theramex, a London-based company focused on women’s health, to private equity firm Cinven. The companies did not disclose the price. A report put it at €2.6 billion, and Cinven is seeking €1.5 billion in debt to help fund the purchase.
Global impact / market context
The borrowing is part of how Cinven plans to pay for the purchase. The reports give different levels of certainty about the price: the companies did not disclose it, while a report cited €2.6 billion. No market reaction is provided.
What to watch
- Check whether the companies disclose the sale price; it would clarify the reported €2.6 billion figure.
- Check whether Cinven secures the sought €1.5 billion in debt; it would show whether this planned funding is obtained.
- Check for further updates on the agreed sale; they could clarify the status of the purchase.
Affected assets
- Theramex
Evidence
- Infoway News — Cinven Seeks €1.5 Billion in Debt for Theramex Acquisition
- Infoway News — Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven
- Infoway News — Cinven To Buy Women'S Health Group Theramex In €2.6 Billion Deal - FT
- Incident timeline — Cinven Seeks €1.5 Billion in Debt for Theramex Acquisition
- Incident timeline — Carlyle and PAI Partners agree to sell pharma company Theramex to Cinven
- Incident timeline — Cinven To Buy Women'S Health Group Theramex In €2.6 Billion Deal - FT